ACHAccendra Health Inc.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Edward A. Pesicka

Location

Virginia, USA

Exchange

NYSE

Website

https://owens-minor.com

Summary

Owens & Minor, Inc.

Company Info

CEO

Edward A. Pesicka

Location

Virginia, USA

Exchange

NYSE

Website

https://owens-minor.com

Summary

Owens & Minor, Inc.

AI Insights for ACH
5 min read

Quick Summary

Accendra Health Inc., formerly associated with Owens & Minor operations, is presented in the data as a healthcare solutions company headquartered in Mechanicsville, Virginia. The company serves the U.S. and international healthcare markets through operations that include distribution, logistics, outsourced services, and manufactured or sourced medical-surgical products. Its Global Solutions activities support healthcare providers, alternate-site care providers, payers, and home-based care channels by helping move medical products and services through complex supply chains. Its Global Products activities focus on medical-surgical products used to reduce healthcare-associated infections and support routine clinical care. The company’s main customers include hospitals, health systems, home healthcare patients, payers, integrated delivery networks, clinics, and other healthcare providers that need reliable product access and operational support.

Strengths

•

The company’s main strength is its established position in healthcare supply chain services and medical-surgical product distribution.

•

It operates in markets with durable demand because healthcare providers and home-care patients need medical supplies regardless of short-term economic cycles.

•

The company also has a large employee base and operational infrastructure that can support broad service coverage.

•

Its strategic focus on Byram and Apria may give it exposure to home healthcare and patient-centered supply channels, which are areas with long-term growth potential.

•

Another strength is that management has identified clear priorities, including cost cuts, debt reduction, technology-driven efficiency, and free cash flow improvement.

Key Risks

•

The largest risk is that the company’s turnaround may take longer than expected or fail to restore sustainable profitability.

•

A lost major payer could reduce revenue and create operating deleverage if fixed costs cannot be removed quickly enough.

•

Inflation, labor costs, freight costs, sourcing disruption, and possible tariffs could pressure margins in both distribution and product operations.

•

The company also operates in competitive markets where larger rivals can use scale, pricing, technology, and supplier relationships to win business.

What to Watch

During the most recent reported period, the company showed revenue of $613.234 million and gross profit of $263.407 million, but it also reported negative operating income and negative net income.
The quarter appears to reflect a business still under pressure from restructuring, margin challenges, and the aftermath of portfolio changes.
Recent company-related news indicates that management has been divesting noncore businesses and narrowing the strategic focus toward Byram and Apria.
The business also appears to be dealing with the effects of a lost major payer, inflation, and stranded costs that may continue to affect near-term results.
No major new product launch or partnership is identified in the provided company-specific news, so the most important quarter event is the ongoing strategic repositioning and operational turnaround effort.

Price Drivers

•

The stock price is being driven primarily by weak profitability, negative EPS, and investor concern about the company’s ability to restore margins.

•

The data shows BasicEPS and DilutedEPS of -1.16, net income of negative $89.07 million, and operating income of negative $35.15 million, which indicate that the market is likely focused on turnaround execution rather than current earnings strength.

•

Recent news says 2026 is expected to be weaker due to the loss of a major payer, inflation, and stranded costs, all of which are meaningful negative price drivers.

•

The stock also has a high beta of 1.525, suggesting that it may move sharply with broader market sentiment and risk appetite.

•

Positive price drivers could include cost reductions, debt reduction, stronger free cash flow, stabilization in payer relationships, and evidence that Byram and Apria can grow profitably.

Recent News

•

Recent company-specific news says Accendra Health reported 2025 revenue of nearly $2.8 billion, up about 3%, but EBITDA declined.

•

The company has divested noncore businesses and is focusing more narrowly on Byram and Apria.

•

Management expects 2026 to be weaker because of a lost major payer, inflation, and stranded costs.

•

The company has outlined priorities that include cost cuts, debt reduction, technology-enabled efficiency improvements, and at least $100 million in free cash flow.

•

Other provided news items relate to ACH payment networks and fintech developments rather than Accendra Health itself, so they do not appear to be directly material to the company’s operating story.

Market Trends

•

The company is affected by several broad healthcare and supply-chain trends.

•

Healthcare providers are trying to reduce costs, improve procurement efficiency, and manage inflation, which can pressure suppliers and distributors to offer better pricing and service.

•

Care is increasingly shifting toward home and alternate-site settings, which could benefit businesses like Byram and Apria if execution is strong.

•

At the same time, reimbursement pressure, payer consolidation, and cautious healthcare spending can create headwinds for companies dependent on payer relationships and healthcare utilization.

•

Broader market volatility also matters because the stock has a high beta and weak current earnings, making investor sentiment toward turnaround and small-cap healthcare names especially important.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on ACH

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show